Registry of haploidentical stem cell transplant for adult blood diseases
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial documents the experience of adults receiving a partially matched (haploidentical) stem cell transplant for blood cancers or severe blood disorders when no fully matched donor is available. It aims to track outcomes and improve future care for people who need this type of transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer or serious blood disorder (like leukemia, lymphoma, myelodysplastic syndrome, or severe aplastic anemia).
- No fully matched sibling or unrelated bone marrow donor is available, and other treatment options haven't worked.
- You are physically active enough to perform daily tasks (ECOG score 0–2).
- You are over 18 years old and can give informed consent.
- Your liver and kidney function (AST, ALT, creatinine) and heart function (ejection fraction) are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.